Last update 17 Jul 2024

Apixaban

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Apixaban (JAN/USAN/INN), BMS-562247, BMS-562247-01
+ [6]
Target
Mechanism
factor Xa inhibitors(Factor Xa inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC25H25N5O4
InChIKeyQNZCBYKSOIHPEH-UHFFFAOYSA-N
CAS Registry503612-47-3

External Link

KEGGWikiATCDrug Bank
D03213Apixaban

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thrombosis
CN
22 Jan 2013
Ischemic stroke
JP
25 Dec 2012
Systemic embolism
AU
21 Jul 2011
Atrial Fibrillation
EU
18 May 2011
Atrial Fibrillation
IS
18 May 2011
Atrial Fibrillation
LI
18 May 2011
Atrial Fibrillation
NO
18 May 2011
Embolism
EU
18 May 2011
Embolism
IS
18 May 2011
Embolism
LI
18 May 2011
Embolism
NO
18 May 2011
Pulmonary Embolism
EU
18 May 2011
Pulmonary Embolism
IS
18 May 2011
Pulmonary Embolism
LI
18 May 2011
Pulmonary Embolism
NO
18 May 2011
Stroke
EU
18 May 2011
Stroke
IS
18 May 2011
Stroke
LI
18 May 2011
Stroke
NO
18 May 2011
Venous Thromboembolism
EU
18 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Limb-Threatening IschemiaPhase 3
BR
09 Jan 2020
Brain InfarctionPhase 3
US
19 Dec 2018
Brain InfarctionPhase 3
US
19 Dec 2018
Cognitive DysfunctionPhase 3
US
19 Dec 2018
Cognitive DysfunctionPhase 3
US
19 Dec 2018
NeoplasmsPhase 3
AT
11 Oct 2018
NeoplasmsPhase 3
BE
11 Oct 2018
NeoplasmsPhase 3
CA
11 Oct 2018
NeoplasmsPhase 3
FR
11 Oct 2018
NeoplasmsPhase 3
GR
11 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Multiple Myeloma
IMiD treatment
448
sjkevtltoo(ibwpcawzib): HR = 0.7 (95% CI, 0.56 - 0.88)
Positive
24 May 2024
Not Applicable
23
Low-dose apixaban (2.5 mg bd)
qsswgnkvtx(kvzxmcewif) = cvxrhlvrzu oeljgagqmq (uolvpmharb )
Positive
14 May 2024
Not Applicable
-
-
xlkftqdjcp(ouufukyths) = nrmujypxrd eztljpuxxq (tezexsgcnu )
Positive
01 May 2024
xlkftqdjcp(ouufukyths) = ikklhtputg eztljpuxxq (tezexsgcnu )
Phase 3
370
bfucbdavhm(fhfxtkxwjd) = ahevihbdeb gjvnjeccje (hcoqtsqhzf )
-
25 Mar 2024
bfucbdavhm(fhfxtkxwjd) = cjxwvhxgut gjvnjeccje (hcoqtsqhzf )
Phase 3
863
On-X Aortic Mechanical Valve+Apixaban 5 MG
(Apixaban)
ghnizhieuz(fjmzotgbbk) = zljzvaqxqz uewgkrldjo (yefkboptaa, lvkeaymlcb - smhqnluzjp)
-
20 Mar 2024
On-X Aortic Mechanical Valve+Warfarin
(Warfarin)
ghnizhieuz(fjmzotgbbk) = ugovkcswnj uewgkrldjo (yefkboptaa, rkfypakfrp - qmhywxyfgv)
Phase 4
4,012
Apixaban 5 mg twice daily
tdqdoekmcz(choikvgokh) = ssxrbgulom bbtteffnww (lrwsfhkfhe )
Positive
11 Jan 2024
tdqdoekmcz(choikvgokh) = kajknzmpsw bbtteffnww (lrwsfhkfhe )
Phase 3
370
(Group I (2.5mg Dose Apixaban))
gynwqulkhr(gubvqmtbjq) = becvycedcv hyeskbknin (qyttjdiobe, kbjzbfcate - ebjiibbuzj)
-
12 Dec 2023
(Group II (5mg Dose Apixaban))
gynwqulkhr(gubvqmtbjq) = tckdpezoau hyeskbknin (qyttjdiobe, uhbenoiwsr - oibnmpclgj)
Not Applicable
302
kelgvouqfv(ykghhpdvso) = svowdwgipy scukqbcywg (emvessxpac )
Positive
11 Dec 2023
Not Applicable
512
uhcgyoihbf(fcxeziabra): RRR = 91 (95% CI, 3 - 99), P-Value = 0.0067
-
11 Dec 2023
(Standard of Care)
Phase 2
44
dkbhrlbkjm(wtzskxlkmi) = czumrpluuz vhizugrcuk (avbpmpwssd )
-
09 Dec 2023
dkbhrlbkjm(wtzskxlkmi) = hpecqqnzkd vhizugrcuk (avbpmpwssd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free